Appendix Table 1.
Vulnerable population | HR | (95% CI) |
---|---|---|
Among MSM males alone | ||
Black vs. nonblack | 1.16 | (1.05, 1.27) |
Among non-MSM males alone | ||
Black vs. nonblack | 1.21 | (1.13, 1.29) |
IDU vs. non-IDU | 1.31 | (1.22, 1.4) |
Among females alone | ||
Black vs. nonblack | 1.05 | (0.94, 1.17) |
IDU vs. non-IDU | 1.16 | (1.01, 1.34) |
Among black, non-IDU patients alone | ||
Non-MSM male vs. non-IDU female | 1.26 | (1.14, 1.4) |
MSM male vs. non-IDU female | 1.08 | (0.97, 1.2) |
Among white, non-IDU patients alone | ||
Non-MSM male vs. non-IDU female | 1.18 | (0.98, 1.43) |
MSM male vs. non-IDU female | 1.08 | (0.92, 1.26) |
Each model accounted for competing risk of death before discontinuity and adjusted for age, baseline CD4+ count, nadir CD4+ count after ART initiation, and cohort site.
Bold estimates are statistically significant (p < 0.05).